Assessing Amivantamab/Lazertinib for Patients With EGFR-Mutated NSCLC

Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses the combination of amivantamab-vmjw (Rybrevant) and lazertinib (Leclaza) for patients with relapsed or refractory EGFR-mutant non–small cell lung cancer (NSCLC) and findings presented at the 2022 IASLC World Conference on Lung Cancer.

The combination is currently being evaluated in the phase 1 CHRYSALIS-2 trial (NCT04077463). In the study, multiple cohorts are being evaluated to assess both amivantamab and lazertinib alone in a variety of patient populations. The trial will also assess amivantamab and lazertinib in combination with chemotherapy.

Findings of CHRYSALIS-2 showed encouraging responses for pretreated patients with EGFR-mutant NSCLC, including an objective response rate of 50% (95% CI, 27%-73%) and a clinical benefit rate of 80% (95% CI, 56%-94%) for all patients (n = 20).

Transcription:

0:08 | One of the things, and there are a few [that were] presented this year, but 1 of the major presentations was a minioral presentation, which is combining amivantamab and lazertinib with chemotherapy. This is something we are looking at both for safety as well as to guide for the therapies, both in the naive setting which is a separate study, as well as the relapsed/refractory setting from CHRYSALIS-2.

0:31 | The implications of the results demonstrate response. We have seen evidence of efficacy of a single-agent, and there's also an oral abstract combining carboplatin pemetrexed said with amivantamab and lazertinib. The responses appear to be pretty promising. The response rate for drug combination is 50%, clinical benefit rate of 80%, which is a partial response plus stable disease, including its central nervous system responses and several of these patients had already gotten chemotherapy, telling us that these drugs work, they are efficacious, and they can help overcome resistance to chemotherapy. It is the guide for future therapies, some of which are ongoing right now, both after osimertinib [Tagrisso] with some chemo combination cocktails, as well as the naive setting.